Stoke Therapeutics
STOK
183 hedge funds and large institutions have $2.13B invested in Stoke Therapeutics in 2025 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 54 increasing their positions, 58 reducing their positions, and 13 closing their positions.
707% more call options, than puts
Call options by funds: $20.3M | Put options by funds: $2.51M
254% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 13
35% more capital invested
Capital invested by funds: $1.57B → $2.13B (+$552M)
21% more funds holding
Funds holding: 151 → 183 (+32)
7% less repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 58
6.26% less ownership
Funds ownership: 123.53% → 117.28% (-6.3%)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$54.8M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$33.6M |
| 3 |
State Street
Boston,
Massachusetts
|
+$32.2M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$18.3M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$13.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$39M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$38M |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$27.5M |
| 4 |
BlackRock
New York
|
-$23.3M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$18.1M |
STOK Hedge Fund Activity: Q4 2025 in Review
183 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q4 2025, worth a combined $2.13B — up 35% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new STOK positions and 13 closed out — a net gain of 33 holders — while 54 added to existing stakes and 58 trimmed.
The largest buyer was Deerfield Management, opening a new position worth an estimated $54.8M. The largest seller was Baker Bros. Advisors, cutting an estimated $39M.
- 183 institutional investors held Stoke Therapeutics (STOK) as of Q4 2025, up from 151 in Q3 2025.
- Funds reported $2.13B of Stoke Therapeutics stock for Q4 2025, up 35% quarter-over-quarter.
- 46 funds opened new Stoke Therapeutics positions in Q4 2025 and 13 closed out, a net change of +33 holders.
- The largest Stoke Therapeutics buyer in Q4 2025 was Deerfield Management, an estimated $54.8M added.
- The largest Stoke Therapeutics seller in Q4 2025 was Baker Bros. Advisors, an estimated $39M sold.
Based on aggregated 13F filings for Q4 2025.